{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T19:30:01Z","timestamp":1769196601935,"version":"3.49.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100013428","name":"Stichting Spieren voor Spieren","doi-asserted-by":"publisher","award":["W.OS18-01"],"award-info":[{"award-number":["W.OS18-01"]}],"id":[{"id":"10.13039\/501100013428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013428","name":"Stichting Spieren voor Spieren","doi-asserted-by":"publisher","award":["W.OS18-01"],"award-info":[{"award-number":["W.OS18-01"]}],"id":[{"id":"10.13039\/501100013428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004243","name":"Prinses Beatrix Spierfonds","doi-asserted-by":"publisher","award":["W.OS18-01"],"award-info":[{"award-number":["W.OS18-01"]}],"id":[{"id":"10.13039\/501100004243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004243","name":"Prinses Beatrix Spierfonds","doi-asserted-by":"publisher","award":["W.OS18-01"],"award-info":[{"award-number":["W.OS18-01"]}],"id":[{"id":"10.13039\/501100004243","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Hereditary spinal muscular atrophy (SMA) is a motor neuron disorder with a wide range in severity in children and adults. Two therapies that alter splicing of the <jats:italic>Survival Motor Neuron 2<\/jats:italic><jats:italic>\u00a0(SMN2)<\/jats:italic> gene, i.e. nusinersen and risdiplam, improve motor function in SMA, but treatment effects vary. Experimental studies indicate that motor unit dysfunction encompasses multiple features, including abnormal function of the motor neuron, axon, neuromuscular junction and muscle fibres. The relative contributions of dysfunction of different parts of the motor unit to the clinical phenotype are unknown. Predictive biomarkers for clinical efficacy are currently lacking. The goals of this project are to study the association of electrophysiological abnormalities of the peripheral motor system in relation to 1) SMA clinical phenotypes and 2) treatment response in patients treated with <jats:italic>SMN2<\/jats:italic>-splicing modifiers (nusinersen or risdiplam).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We designed an investigator-initiated, monocentre, longitudinal cohort study using electrophysiological techniques (\u2018the SMA Motor Map\u2019) in Dutch children (\u2265\u200912\u00a0years) and adults with SMA types 1\u20134. The protocol includes the compound muscle action potential scan, nerve excitability testing and repetitive nerve stimulation test, executed unilaterally at the median nerve. Part one cross-sectionally assesses the association of electrophysiological abnormalities in relation to SMA clinical phenotypes in treatment-na\u00efve patients. Part two investigates the predictive value of electrophysiological changes at two-months treatment for a positive clinical motor response after one-year treatment with <jats:italic>SMN2<\/jats:italic>-splicing modifiers. We will include 100 patients in each part of the study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This study will provide important information on the pathophysiology of the peripheral motor system of treatment-na\u00efve patients with SMA through electrophysiological techniques. More importantly, the longitudinal analysis in patients on <jats:italic>SMN2<\/jats:italic>-splicing modifying therapies (i.e. nusinersen and risdiplam) intents to develop non-invasive electrophysiological biomarkers for treatment response in order to improve (individualized) treatment decisions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>NL72562.041.20 (registered at <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.toetsingonline.nl\">https:\/\/www.toetsingonline.nl<\/jats:ext-link>. 26\u201303-2020).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12883-023-03207-5","type":"journal-article","created":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T08:02:41Z","timestamp":1682323361000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Longitudinal prospective cohort study to assess peripheral motor function with extensive electrophysiological techniques in patients with Spinal Muscular Atrophy (SMA): the SMA Motor Map protocol"],"prefix":"10.1186","volume":"23","author":[{"given":"Leandra A. A.","family":"Ros","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. Stephan","family":"Goedee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hessel","family":"Franssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fay-Lynn","family":"Asselman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart","family":"Bartels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inge","family":"Cuppen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruben P. A.","family":"van Eijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boudewijn T. H. M.","family":"Sleutjes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. Ludo","family":"van der Pol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renske I.","family":"Wadman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,24]]},"reference":[{"issue":"1","key":"3207_CR1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre S, Burglen L, Reboullet S, Clermont O, Burlet P, Viollet L, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80(1):155\u201365. https:\/\/doi.org\/10.1016\/0092-8674(95)90460-3.","journal-title":"Cell"},{"issue":"5","key":"3207_CR2","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S1474-4422(12)70061-3","volume":"11","author":"E Mercuri","year":"2012","unstructured":"Mercuri E, Bertini E, Iannaccone ST. Childhood spinal muscular atrophy: controversies and challenges. Lancet Neurol. 2012;11(5):443\u201352. https:\/\/doi.org\/10.1016\/S1474-4422(12)70061-3.","journal-title":"Lancet Neurol"},{"issue":"20","key":"3207_CR3","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1212\/WNL.0b013e3182749eca","volume":"79","author":"RI Wadman","year":"2012","unstructured":"Wadman RI, Vrancken AF, van den Berg LH, van der Pol WL. Dysfunction of the neuromuscular junction in spinal muscular atrophy types 2 and 3. Neurology. 2012;79(20):2050\u20135. https:\/\/doi.org\/10.1212\/WNL.0b013e3182749eca.","journal-title":"Neurology"},{"issue":"4","key":"3207_CR4","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1093\/brain\/awab411","volume":"145","author":"LE Habets","year":"2022","unstructured":"Habets LE, Bartels B, Asselman FL, Hooijmans MT, van den Berg S, Nederveen AJ, et al. Magnetic resonance reveals mitochondrial dysfunction and muscle remodelling in spinal muscular atrophy. Brain. 2022;145(4):1422\u201335. https:\/\/doi.org\/10.1093\/brain\/awab411.","journal-title":"Brain"},{"issue":"10","key":"3207_CR5","doi-asserted-by":"publisher","first-page":"e4357","DOI":"10.1002\/nbm.4357","volume":"33","author":"LAM Otto","year":"2020","unstructured":"Otto LAM, van der Pol WL, Schlaffke L, Wijngaarde CA, Stam M, Wadman RI, et al. Quantitative MRI of skeletal muscle in a cross-sectional cohort of patients with spinal muscular atrophy types 2 and 3. NMR Biomed. 2020;33(10):e4357. https:\/\/doi.org\/10.1002\/nbm.4357.","journal-title":"NMR Biomed"},{"issue":"25","key":"3207_CR6","doi-asserted-by":"publisher","first-page":"8703","DOI":"10.1523\/JNEUROSCI.0204-12.2012","volume":"32","author":"TL Martinez","year":"2012","unstructured":"Martinez TL, Kong L, Wang X, Osborne MA, Crowder ME, Van Meerbeke JP, et al. Survival motor neuron protein in motor neurons determines synaptic integrity in spinal muscular atrophy. J Neurosci. 2012;32(25):8703\u201315. https:\/\/doi.org\/10.1523\/JNEUROSCI.0204-12.2012.","journal-title":"J Neurosci"},{"issue":"18","key":"3207_CR7","doi-asserted-by":"publisher","first-page":"4745","DOI":"10.1093\/hmg\/ddu189","volume":"23","author":"KV Bricceno","year":"2014","unstructured":"Bricceno KV, Martinez T, Leikina E, Duguez S, Partridge TA, Chernomordik LV, et al. Survival motor neuron protein deficiency impairs myotube formation by altering myogenic gene expression and focal adhesion dynamics. Hum Mol Genet. 2014;23(18):4745\u201357. https:\/\/doi.org\/10.1093\/hmg\/ddu189.","journal-title":"Hum Mol Genet"},{"issue":"3","key":"3207_CR8","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1172\/JCI131989","volume":"130","author":"JK Kim","year":"2020","unstructured":"Kim JK, Jha NN, Feng Z, Faleiro MR, Chiriboga CA, Wei-Lapierre L, et al. Muscle-specific SMN reduction reveals motor neuron-independent disease in spinal muscular atrophy models. J Clin Invest. 2020;130(3):1271\u201387. https:\/\/doi.org\/10.1172\/JCI131989.","journal-title":"J Clin Invest"},{"issue":"8","key":"3207_CR9","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrn2670","volume":"10","author":"AH Burghes","year":"2009","unstructured":"Burghes AH, Beattie CE. Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick? Nat Rev Neurosci. 2009;10(8):597\u2013609. https:\/\/doi.org\/10.1038\/nrn2670.","journal-title":"Nat Rev Neurosci"},{"issue":"1","key":"3207_CR10","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13023-020-01367-y","volume":"15","author":"CA Wijngaarde","year":"2020","unstructured":"Wijngaarde CA, Veldhoen ES, van Eijk RPA, Stam M, Otto LAM, Asselman FL, et al. Natural history of lung function in spinal muscular atrophy. Orphanet J Rare Dis. 2020;15(1):88. https:\/\/doi.org\/10.1186\/s13023-020-01367-y.","journal-title":"Orphanet J Rare Dis"},{"issue":"14","key":"3207_CR11","doi-asserted-by":"publisher","first-page":"e1988","DOI":"10.1212\/WNL.0000000000010540","volume":"95","author":"CA Wijngaarde","year":"2020","unstructured":"Wijngaarde CA, Stam M, Otto LAM, Bartels B, Asselman FL, van Eijk RPA, et al. Muscle strength and motor function in adolescents and adults with spinal muscular atrophy. Neurology. 2020;95(14):e1988\u201398. https:\/\/doi.org\/10.1212\/WNL.0000000000010540.","journal-title":"Neurology"},{"issue":"2","key":"3207_CR12","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1212\/WNL.0000000000007742","volume":"93","author":"CA Wijngaarde","year":"2019","unstructured":"Wijngaarde CA, Brink RC, de Kort FAS, Stam M, Otto LAM, Asselman FL, et al. Natural course of scoliosis and lifetime risk of scoliosis surgery in spinal muscular atrophy. Neurology. 2019;93(2):e149\u201358. https:\/\/doi.org\/10.1212\/WNL.0000000000007742.","journal-title":"Neurology"},{"issue":"3","key":"3207_CR13","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/ene.13534","volume":"25","author":"RI Wadman","year":"2018","unstructured":"Wadman RI, Wijngaarde CA, Stam M, Bartels B, Otto LAM, Lemmink HH, et al. Muscle strength and motor function throughout life in a cross-sectional cohort of 180 patients with spinal muscular atrophy types 1c\u20134. Eur J Neurol. 2018;25(3):512\u20138. https:\/\/doi.org\/10.1111\/ene.13534.","journal-title":"Eur J Neurol"},{"issue":"12","key":"3207_CR14","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1212\/WNL.0000000000000796","volume":"83","author":"RI Wadman","year":"2014","unstructured":"Wadman RI, van Bruggen HW, Witkamp TD, Sparreboom-Kalaykova SI, Stam M, van den Berg LH, et al. Bulbar muscle MRI changes in patients with SMA with reduced mouth opening and dysphagia. Neurology. 2014;83(12):1060\u20136. https:\/\/doi.org\/10.1212\/WNL.0000000000000796.","journal-title":"Neurology"},{"issue":"18","key":"3207_CR15","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al. Nusinersen versus Sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377(18):1723\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1702752.","journal-title":"N Engl J Med"},{"issue":"7","key":"3207_CR16","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","volume":"378","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, et al. Nusinersen versus Sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018;378(7):625\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1710504.","journal-title":"N Engl J Med"},{"issue":"10","key":"3207_CR17","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1056\/NEJMoa2009965","volume":"384","author":"G Baranello","year":"2021","unstructured":"Baranello G, Darras BT, Day JW, Deconinck N, Klein A, Masson R, et al. Risdiplam in type 1 spinal muscular atrophy. N Engl J Med. 2021;384(10):915\u201323. https:\/\/doi.org\/10.1056\/NEJMoa2009965.","journal-title":"N Engl J Med"},{"issue":"1","key":"3207_CR18","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S1474-4422(21)00367-7","volume":"21","author":"E Mercuri","year":"2022","unstructured":"Mercuri E, Deconinck N, Mazzone ES, Nascimento A, Oskoui M, Saito K, et al. Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2022;21(1):42\u201352. https:\/\/doi.org\/10.1016\/S1474-4422(21)00367-7.","journal-title":"Lancet Neurol"},{"issue":"10","key":"3207_CR19","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","volume":"86","author":"CA Chiriboga","year":"2016","unstructured":"Chiriboga CA, Swoboda KJ, Darras BT, Iannaccone ST, Montes J, De Vivo DC, et al. Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy. Neurology. 2016;86(10):890\u20137. https:\/\/doi.org\/10.1212\/WNL.0000000000002445.","journal-title":"Neurology"},{"issue":"15","key":"3207_CR20","doi-asserted-by":"publisher","first-page":"6501","DOI":"10.1021\/acs.jmedchem.8b00741","volume":"61","author":"H Ratni","year":"2018","unstructured":"Ratni H, Ebeling M, Baird J, Bendels S, Bylund J, Chen KS, et al. Discovery of Risdiplam, a selective Survival of Motor Neuron-2 ( SMN2) gene splicing modifier for the treatment of Spinal Muscular Atrophy (SMA). J Med Chem. 2018;61(15):6501\u201317. https:\/\/doi.org\/10.1021\/acs.jmedchem.8b00741.","journal-title":"J Med Chem"},{"issue":"6","key":"3207_CR21","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1016\/j.clinph.2020.01.018","volume":"131","author":"B Sleutjes","year":"2020","unstructured":"Sleutjes B, Wijngaarde CA, Wadman RI, Otto LAM, Asselman FL, Cuppen I, et al. Assessment of motor unit loss in patients with spinal muscular atrophy. Clin Neurophysiol. 2020;131(6):1280\u20136. https:\/\/doi.org\/10.1016\/j.clinph.2020.01.018.","journal-title":"Clin Neurophysiol"},{"issue":"5","key":"3207_CR22","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/ana.20473","volume":"57","author":"KJ Swoboda","year":"2005","unstructured":"Swoboda KJ, Prior TW, Scott CB, McNaught TP, Wride MC, Reyna SP, et al. Natural history of denervation in SMA: relation to age, SMN2 copy number, and function. Ann Neurol. 2005;57(5):704\u201312. https:\/\/doi.org\/10.1002\/ana.20473.","journal-title":"Ann Neurol"},{"issue":"3","key":"3207_CR23","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/mus.10050","volume":"25","author":"MB Bromberg","year":"2002","unstructured":"Bromberg MB, Swoboda KJ. Motor unit number estimation in infants and children with spinal muscular atrophy. Muscle Nerve. 2002;25(3):445\u20137. https:\/\/doi.org\/10.1002\/mus.10050.","journal-title":"Muscle Nerve"},{"issue":"9","key":"3207_CR24","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1111\/ene.15005","volume":"28","author":"C Schneider","year":"2021","unstructured":"Schneider C, Wassermann MK, Grether NB, Fink GR, Wunderlich G, Lehmann HC. Motor unit number estimation in adult patients with spinal muscular atrophy treated with nusinersen. Eur J Neurol. 2021;28(9):3022\u20139. https:\/\/doi.org\/10.1111\/ene.15005.","journal-title":"Eur J Neurol"},{"issue":"1","key":"3207_CR25","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1136\/jnnp-2020-324254","volume":"92","author":"D Kariyawasam","year":"2020","unstructured":"Kariyawasam D, D\u2019Silva A, Howells J, Herbert K, Geelan-Small P, Lin CS, et al. Motor unit changes in children with symptomatic spinal muscular atrophy treated with nusinersen. J Neurol Neurosurg Psychiatry. 2020;92(1):78\u201385. https:\/\/doi.org\/10.1136\/jnnp-2020-324254.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"Pt 11","key":"3207_CR26","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.1093\/brain\/awr229","volume":"134","author":"MA Farrar","year":"2011","unstructured":"Farrar MA, Vucic S, Lin CS, Park SB, Johnston HM, du Sart D, et al. Dysfunction of axonal membrane conductances in adolescents and young adults with spinal muscular atrophy. Brain. 2011;134(Pt 11):3185\u201397. https:\/\/doi.org\/10.1093\/brain\/awr229.","journal-title":"Brain"},{"issue":"1","key":"3207_CR27","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1113\/JP282249","volume":"600","author":"DST Kariyawasam","year":"2022","unstructured":"Kariyawasam DST, D\u2019Silva AM, Herbert K, Howells J, Carey K, Kandula T, et al. Axonal excitability changes in children with spinal muscular atrophy treated with nusinersen. J Physiol. 2022;600(1):95\u2013109. https:\/\/doi.org\/10.1113\/JP282249.","journal-title":"J Physiol"},{"issue":"2","key":"3207_CR28","doi-asserted-by":"publisher","first-page":"e000164","DOI":"10.1136\/bmjno-2021-000164","volume":"3","author":"WD Arnold","year":"2021","unstructured":"Arnold WD, Severyn S, Zhao S, Kline D, Linsenmayer M, Kelly K, et al. Persistent neuromuscular junction transmission defects in adults with spinal muscular atrophy treated with nusinersen. BMJ Neurol Open. 2021;3(2):e000164. https:\/\/doi.org\/10.1136\/bmjno-2021-000164.","journal-title":"BMJ Neurol Open"},{"issue":"3","key":"3207_CR29","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1002\/mus.26621","volume":"60","author":"MO Kovalchuk","year":"2019","unstructured":"Kovalchuk MO, Franssen H, Scheijmans FEV, Van Schelven LJ, Van Den Berg LH, Sleutjes B. Warming nerves for excitability testing. Muscle Nerve. 2019;60(3):279\u201385. https:\/\/doi.org\/10.1002\/mus.26621.","journal-title":"Muscle Nerve"},{"issue":"3","key":"3207_CR30","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.jelekin.2010.11.007","volume":"21","author":"EM Maathuis","year":"2011","unstructured":"Maathuis EM, Drenthen J, Visser GH, Blok JH. Reproducibility of the CMAP scan. J Electromyogr Kinesiol. 2011;21(3):433\u20137. https:\/\/doi.org\/10.1016\/j.jelekin.2010.11.007.","journal-title":"J Electromyogr Kinesiol"},{"issue":"1","key":"3207_CR31","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1749-7221-7-4","volume":"7","author":"EM Maathuis","year":"2012","unstructured":"Maathuis EM, Henderson RD, Drenthen J, Hutchinson NM, Daube JR, Blok JH, et al. Optimal stimulation settings for CMAP scan registrations. J Brachial Plex Peripher Nerve Inj. 2012;7(1):4. https:\/\/doi.org\/10.1186\/1749-7221-7-4.","journal-title":"J Brachial Plex Peripher Nerve Inj"},{"key":"3207_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-324254","author":"D Kariyawasam","year":"2020","unstructured":"Kariyawasam D, D\u2019Silva A, Howells J, Herbert K, Geelan-Small P, Lin CS, et al. Motor unit changes in children with symptomatic spinal muscular atrophy treated with nusinersen. J Neurol Neurosurg Psychiatry. 2020. https:\/\/doi.org\/10.1136\/jnnp-2020-324254.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"3207_CR33","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1002\/mus.24945","volume":"53","author":"H Bostock","year":"2016","unstructured":"Bostock H. Estimating motor unit numbers from a CMAP scan. Muscle Nerve. 2016;53(6):889\u201396. https:\/\/doi.org\/10.1002\/mus.24945.","journal-title":"Muscle Nerve"},{"key":"3207_CR34","doi-asserted-by":"publisher","unstructured":"Jacobsen AB, Bostock H and Tankisi H. CMAP Scan MUNE (MScan) - a novel Motor Unit Number Estimation (MUNE) Method. J Vis Exp. 2018(136). https:\/\/doi.org\/10.3791\/56805","DOI":"10.3791\/56805"},{"issue":"3","key":"3207_CR35","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/ana.20395","volume":"57","author":"MC Kiernan","year":"2005","unstructured":"Kiernan MC, Isbister GK, Lin CS, Burke D, Bostock H. Acute tetrodotoxin-induced neurotoxicity after ingestion of puffer fish. Ann Neurol. 2005;57(3):339\u201348. https:\/\/doi.org\/10.1002\/ana.20395.","journal-title":"Ann Neurol"},{"issue":"7","key":"3207_CR36","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1113\/jphysiol.2011.225573","volume":"590","author":"J Howells","year":"2012","unstructured":"Howells J, Trevillion L, Bostock H, Burke D. The voltage dependence of I(h) in human myelinated axons. J Physiol. 2012;590(7):1625\u201340. https:\/\/doi.org\/10.1113\/jphysiol.2011.225573.","journal-title":"J Physiol"},{"issue":"9","key":"3207_CR37","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1002\/mus.1140","volume":"24","author":"Medicine AQACAAoE","year":"2001","unstructured":"Medicine AQACAAoE. Literature review of the usefulness of repetitive nerve stimulation and single fiber EMG in the electrodiagnostic evaluation of patients with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome. Muscle Nerve. 2001;24(9):1239\u201347. https:\/\/doi.org\/10.1002\/mus.1140.","journal-title":"Muscle Nerve"},{"issue":"4","key":"3207_CR38","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/mus.20389","volume":"32","author":"SJ Oh","year":"2005","unstructured":"Oh SJ, Kurokawa K, Claussen GC, Ryan HF Jr. Electrophysiological diagnostic criteria of Lambert-Eaton myasthenic syndrome. Muscle Nerve. 2005;32(4):515\u201320. https:\/\/doi.org\/10.1002\/mus.20389.","journal-title":"Muscle Nerve"},{"issue":"7","key":"3207_CR39","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/nn.4561","volume":"20","author":"EV Fletcher","year":"2017","unstructured":"Fletcher EV, Simon CM, Pagiazitis JG, Chalif JI, Vukojicic A, Drobac E, et al. Reduced sensory synaptic excitation impairs motor neuron function via Kv2.1 in spinal muscular atrophy. Nat Neurosci. 2017;20(7):905\u201316. https:\/\/doi.org\/10.1038\/nn.4561.","journal-title":"Nat Neurosci"},{"issue":"11","key":"3207_CR40","doi-asserted-by":"publisher","first-page":"3818","DOI":"10.1523\/JNEUROSCI.5775-11.2012","volume":"32","author":"RG Gogliotti","year":"2012","unstructured":"Gogliotti RG, Quinlan KA, Barlow CB, Heier CR, Heckman CJ, Didonato CJ. Motor neuron rescue in spinal muscular atrophy mice demonstrates that sensory-motor defects are a consequence, not a cause, of motor neuron dysfunction. J Neurosci. 2012;32(11):3818\u201329. https:\/\/doi.org\/10.1523\/JNEUROSCI.5775-11.2012.","journal-title":"J Neurosci"},{"issue":"6","key":"3207_CR41","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1212\/01.wnl.0000052788.39340.45","volume":"60","author":"S Rudnik-Schoneborn","year":"2003","unstructured":"Rudnik-Schoneborn S, Goebel HH, Schlote W, Molaian S, Omran H, Ketelsen U, et al. Classical infantile spinal muscular atrophy with SMN deficiency causes sensory neuronopathy. Neurology. 2003;60(6):983\u20137. https:\/\/doi.org\/10.1212\/01.wnl.0000052788.39340.45.","journal-title":"Neurology"},{"key":"3207_CR42","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3389\/fnmol.2019.00059","volume":"12","author":"HK Shorrock","year":"2019","unstructured":"Shorrock HK, Gillingwater TH, Groen EJN. Molecular mechanisms underlying sensory-motor circuit dysfunction in SMA. Front Mol Neurosci. 2019;12:59. https:\/\/doi.org\/10.3389\/fnmol.2019.00059.","journal-title":"Front Mol Neurosci"},{"issue":"9\u201310","key":"3207_CR43","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.nmd.2007.05.009","volume":"17","author":"JM O'Hagen","year":"2007","unstructured":"O\u2019Hagen JM, Glanzman AM, McDermott MP, Ryan PA, Flickinger J, Quigley J, et al. An expanded version of the Hammersmith functional motor scale for SMA II and III patients. Neuromuscul Disord. 2007;17(9\u201310):693\u20137. https:\/\/doi.org\/10.1016\/j.nmd.2007.05.009.","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"3207_CR44","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/s1090-3798(03)00060-6","volume":"7","author":"M Main","year":"2003","unstructured":"Main M, Kairon H, Mercuri E, Muntoni F. The Hammersmith functional motor scale for children with spinal muscular atrophy: a scale to test ability and monitor progress in children with limited ambulation. Eur J Paediatr Neurol. 2003;7(4):155\u20139. https:\/\/doi.org\/10.1016\/s1090-3798(03)00060-6.","journal-title":"Eur J Paediatr Neurol"},{"issue":"12","key":"3207_CR45","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1177\/0883073811420294","volume":"26","author":"AM Glanzman","year":"2011","unstructured":"Glanzman AM, O\u2019Hagen JM, McDermott MP, Martens WB, Flickinger J, Riley S, et al. Validation of the expanded Hammersmith functional motor scale in spinal muscular atrophy type II and III. J Child Neurol. 2011;26(12):1499\u2013507. https:\/\/doi.org\/10.1177\/0883073811420294.","journal-title":"J Child Neurol"},{"key":"3207_CR46","doi-asserted-by":"publisher","first-page":"S102","DOI":"10.1016\/j.nmd.2020.08.190","volume":"30","author":"T Duong","year":"2020","unstructured":"Duong T, Pasternak A, Dunaway Young S, Nelson L, Muni Lofra R, Carry T, et al. SMA: registries, biomarkers & outcome measures: P188 ATEND: development of a wheelchair based motor assessment. Neuromuscul Disord. 2020;30:S102. https:\/\/doi.org\/10.1016\/j.nmd.2020.08.190.","journal-title":"Neuromuscul Disord"},{"issue":"6","key":"3207_CR47","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/mus.25430","volume":"55","author":"ES Mazzone","year":"2017","unstructured":"Mazzone ES, Mayhew A, Montes J, Ramsey D, Fanelli L, Young SD, et al. Revised upper limb module for spinal muscular atrophy: development of a new module. Muscle Nerve. 2017;55(6):869\u201374. https:\/\/doi.org\/10.1002\/mus.25430.","journal-title":"Muscle Nerve"},{"issue":"1","key":"3207_CR48","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13023-020-1348-2","volume":"15","author":"B Bartels","year":"2020","unstructured":"Bartels B, de Groot JF, Habets LE, Wijngaarde CA, Vink W, Stam M, et al. Fatigability in spinal muscular atrophy: validity and reliability of endurance shuttle tests. Orphanet J Rare Dis. 2020;15(1):75. https:\/\/doi.org\/10.1186\/s13023-020-1348-2.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"3207_CR49","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/mus.26419","volume":"59","author":"MC Pera","year":"2019","unstructured":"Pera MC, Coratti G, Mazzone ES, Montes J, Scoto M, De Sanctis R, et al. Revised upper limb module for spinal muscular atrophy: 12 month changes. Muscle Nerve. 2019;59(4):426\u201330. https:\/\/doi.org\/10.1002\/mus.26419.","journal-title":"Muscle Nerve"},{"issue":"3","key":"3207_CR50","doi-asserted-by":"publisher","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","volume":"158","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza-Jeric K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200\u20137. https:\/\/doi.org\/10.7326\/0003-4819-158-3-201302050-00583.","journal-title":"Ann Intern Med"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-023-03207-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-023-03207-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-023-03207-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T08:03:02Z","timestamp":1682323382000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-023-03207-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,24]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3207"],"URL":"https:\/\/doi.org\/10.1186\/s12883-023-03207-5","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,24]]},"assertion":[{"value":"14 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Medical Ethics Committee of the University Medical Center Utrecht (No. 20\u2013143 (Version 3) \/NL72562.041.20) and registered in the Dutch registry for clinical studies and trials (). The trial is monitored by an internal party of the University Medical Center Utrecht. The study is conducted according to the principles of the Declaration of Helsinki, adapted 19\u201310-2013, and in accordance with the Medical Research Involving Human Subjects Act (WMO). Informed consent to participate will be obtained from all participants and\/or their parents or legal representative in case of minors. Minors are participants aged 12 through 16\u00a0years old as defined by the regulation of the Dutch Central Committee on Research Involving Human Subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HG has received research grants from Prinses Beatrix spierfonds, travel grants from Shire\/Takeda and speaker fees from Takeda paid to the institution. BB receives research support from the Prinses Beatrix Spierfonds, Stichting Spieren for Spieren and Health Holland, all non-profit foundations. His employer receives fees for SMA-related consultancy activities for Biogen, Novartis, Scholar Rock and Roche. IC provides ad hoc consultancy for AveXis (Novartis). BS and RvE receive research support from the Netherlands ALS foundation. RW receives research support from the Prinses Beatrix Spierfonds and Stichting Spieren voor Spieren. WP serves on the scientific advisory board for SMA Europe, is a member of the Branaplam data monitoring committee for Novartis, provides ad hoc consultancy for Biogen and AveXis (Novartis), and receives research support from the Prinses Beatrix Spierfonds, Vriendenloterij and Stichting Spieren voor Spieren. All other authors have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"164"}}